Loading
Autologous cell therapy batches fail more often than any other medicine because each patient's starting cells behave differently and the process runs without feedback. Inline sensors for metabolites, cell counts and cytokines, feeding models that adjust feeding and harvest timing in real time, could rescue batches that would otherwise be discarded.
Autologous manufacturing has out-of-specification and failure rates far above those of conventional biologics, driven by variable starting material and largely open-loop processes. Inline sensors (metabolites, cell counts, imaging, cytokines), electronic batch records and machine-learning models predicting final yield and potency from early process data allow adaptive feeding, harvest timing and early re-manufacture decisions. The proposal is a shared, anonymised dataset of manufacturing runs across manufacturers and an open model benchmark, with regulatory guidance on adaptive control within a validated design space.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, TIL therapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, TIL therapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.